Cumberland Pharmaceuticals (CPIX) — Customer and Partner Map for Investors

Cumberland Pharmaceuticals operates as a specialty pharmaceutical acquirer, developer and marketer, monetizing primarily through U.S. product sales to wholesale distributors and through territorial licensing and distribution agreements internationally. The company sells branded injectables and hospital-focused medicines, collects most revenue domestically (Revenue TTM $44.5M), and supplements margins with partner royalties and exclusive regional distribution deals. For a concise feed of counterparties and contract signals, visit https://nullexposure.com/.

How Cumberland brings products to market and earns cash

Cumberland’s go‑to‑market model is distribution‑centric: it sells through independent pharmaceutical wholesalers in the U.S. while operating a small direct hospital and oncology sales presence, and relies on international licensing for market expansion. The FY2024 disclosures show high customer concentration (three customers accounted for 29%, 26% and 21% of sales), coupled with meaningful exposure to government pricing programs (Medicaid/340B), which structurally compress net pricing but also embed predictable reimbursement mechanics. These characteristics produce a business that is commercially mature in the U.S. but operationally dependent on a narrow set of distribution partners.

Operating constraints that shape risk and upside

Concentration risk: Top three customers represent the majority of revenue, which increases counterparty risk and working capital sensitivity (accounts receivable from those customers represented over 60% of receivables at year‑end). This is a company‑level signal from the FY2024 10‑K.
Distribution posture: Cumberland’s primary customers are wholesale distributors, not direct national payors; this means revenue is dependent on distributor purchasing patterns and GPO/contracting wins (company 10‑K).
Government pricing exposure: Participation in Medicaid rebates, 340B and ASP reporting creates margin pressure and compliance obligations (company filings).
Internationalization via partners: Cumberland offsets domestic concentration by granting exclusive regional rights to local partners, which transfers regulatory and commercial risk but also limits direct upside capture (PR Newswire releases and FY2024 statements).

If you want the raw relationship listing and contract excerpts for underwriting or diligence, see the issuer hub at https://nullexposure.com/.

Mapping every named customer and partner (compact summaries)

Below are all relationships referenced in the source material with one‑line summaries and source context.

Allergan — Cumberland’s filings mention Dalbavancin (Dalvance) as an Allergan‑sold injectable antibiotic, noted in the FY2024 Form 10‑K that outlines competing products in the acute care market. (Cumberland Form 10‑K, FY2024)
Allergan, Inc. — The company’s 10‑K references Linaclotide (Linzess) sold by Allergan, Inc., cited as part of the competitive landscape for GI products. (Cumberland Form 10‑K, FY2024)
Braintree Laboratories, Inc. — Braintree is identified in the 10‑K as the distributor for lactitol oral solution (Pizensy), a competing constipation therapy. (Cumberland Form 10‑K, FY2024)
Ironwood Pharmaceuticals, Inc. — Ironwood is listed alongside Allergan as a seller of linaclotide (Linzess), cited in the FY2024 competitive overview. (Cumberland Form 10‑K, FY2024)
Otsuka Pharmaceutical Company — Otsuka’s Samsca (tolvaptan) is named in the 10‑K as a competing product in the relevant therapeutic class. (Cumberland Form 10‑K, FY2024)
Pacira Pharmaceuticals, Inc. — Pacira’s Exparel (bupivacaine injectable suspension) appears in the FY2024 filing as a market reference in postoperative analgesia. (Cumberland Form 10‑K, FY2024)
Par Pharmaceuticals, Inc. — Par’s branded Ondansetron (Zuplenz) is referenced in the 10‑K as part of the competition set. (Cumberland Form 10‑K, FY2024)
Roche Pharmaceuticals Inc. — Kytril (injectable granisetron) from Roche is cited in the 10‑K as a relevant branded comparator. (Cumberland Form 10‑K, FY2024)
Tesaro Inc. (GSK division) — Varubi, a branded NK1 antagonist sold by Tesaro (GSK), is referenced in the FY2024 competitive discussion. (Cumberland Form 10‑K, FY2024)
Trevena, Inc. — Trevena’s Olinvyk (oliceridine) is listed in the 10‑K as a new chemical entity in the acute postoperative pain market. (Cumberland Form 10‑K, FY2024)
Vertex Pharmaceuticals, Inc. — Vertex’s Journavx (suzetrigine) is noted as an FDA‑approved non‑opioid pain signal inhibitor (approval referenced in January 2025) in the FY2024 report. (Cumberland Form 10‑K, FY2024)
SciClone Pharmaceuticals — Cumberland announced an exclusive agreement granting SciClone rights to register, promote and distribute Vibativ in China; PR Newswire coverage of Cumberland’s Q4 2025 release describes the arrangement. (PR Newswire, Mar 9, 2026)
Tabuk Pharmaceutical Manufacturing Company — Tabuk holds exclusive rights to register and distribute Vibativ in Saudi Arabia and Jordan with optional regional expansion; documented in PR Newswire releases dating to the partnership announcement. (PR Newswire, FY2022 and Mar 2026 releases)
Perrigo Co. (PRGO) — Historical press coverage cites a distribution agreement allowing Perrigo to distribute Cumberland‑sourced authorized generics upon generic market entry; referenced in news about prior litigation and settlements. (CBS News report summarizing agreements, FY2012)
Hikma Pharmaceuticals PLC — Hikma is named in the FY2024 10‑K as the seller of Combogesic (acetaminophen/ibuprofen injection), a related product category competitor. (Cumberland Form 10‑K, FY2024)
Mallinckrodt plc — Mallinckrodt’s Ofirmev (IV acetaminophen) is referenced in Cumberland’s FY2024 filing as a comparable injectable analgesic. (Cumberland Form 10‑K, FY2024)
PiSA Farmacéutica / PiSA Pharmaceutical — Cumberland has an agreement granting PiSA exclusive supply and distribution rights for its ibuprofen product (Caldolor) in Mexico, with Cumberland providing regulatory and manufacturing support; announced in PR Newswire releases (2022 and Q4 2025 summary). (PR Newswire, FY2023 & Mar 9, 2026)
Premier, Inc. (PINC) — Vibativ was added to a national group purchasing agreement with Premier, expanding hospital access across thousands of facilities; covered in Cumberland press releases and trade reporting in FY2025. (PR Newswire & StockTitan summaries, FY2025)
Vizient — Cumberland secured a contract enabling the Vibativ 4‑Vial Starter Pak to be available through Vizient’s contracting platform, improving procurement reach to member hospitals. (PR Newswire, FY2025)
Synergy Pharmaceuticals — Synergy (Trulance/plecanatide) is listed in the FY2024 filing as a seller within the constipation/IBS therapeutic area. (Cumberland Form 10‑K, FY2024)
SciClone Pharmaceuticals (earlier FY2023 reference) — Previously reported filings indicate SciClone’s regulatory submission acceptance for Vibativ in China (news release summarized in Cumberland’s FY2023 presentation). (PR Newswire, FY2023)
Tabuk Pharmaceutical (FY2023 reference) — Earlier press noted Tabuk’s exclusive distribution and promotion obligations in Saudi Arabia and Jordan; this is the original partnership disclosure. (PR Newswire, FY2023)
Verity Pharmaceuticals — Cumberland announced partnership rights allowing Verity to introduce Vibativ in their market, cited in a corporate press release covering international commercialization in FY2023. (PR Newswire, FY2023)
D.B. Pharm Korea — Cumberland entered into an agreement with D.B. Pharm Korea to register and commercialize Vibativ in South Korea, as described in company news covering international deals. (PR Newswire, FY2023)
RedHill Biopharma (RDHL) — Corporate filings and 8‑Ks referenced in news summaries note strategic arrangements with RedHill Biopharma to jointly commercialize Talicia and other contract amendments (StockTitan summary of CPIX filings, FY2025). (StockTitan news summaries, FY2025)
Melinta (MLNTQ) — Melinta’s Orbactiv (oritavancin) is called out in the FY2024 10‑K as an injectable antibiotic competitor. (Cumberland Form 10‑K, FY2024)
Astellas — Astellas is mentioned for developing and launching Vaprisol, noted historically in the company’s FY2024 filing as part of the product landscape. (Cumberland Form 10‑K, FY2024)
Basilea — Basilea’s Zevetera (ceftobiprole), registered in 2024, is listed in the FY2024 filing as a new injectable antibiotic in the competitive set. (Cumberland Form 10‑K, FY2024)

What investors should take away

Concentration and distributor dependency are the dominant commercial risks. Three customers account for the majority of revenue and Cumberland sells predominantly through wholesalers; payment timing or contract shifts at those distributors will materially affect cash flow. (Cumberland Form 10‑K, FY2024)
International licensing is a deliberate mitigation strategy. Exclusive distributor agreements (Tabuk, SciClone, PiSA, D.B. Pharm Korea, Verity) reduce regulatory and commercialization expense while providing localized revenue streams; those agreements trade upside for lower capital intensity (company press releases, FY2022–FY2026).
Reimbursement and government programs matter. Participation in Medicaid rebates and 340B influences net pricing and requires compliance infrastructure — a structural margin constraint noted in filings. (Cumberland Form 10‑K)

If you are modeling counterparty risk or benchmarking concentration exposure, see our issuer hub for Cumberland’s relationship matrix at https://nullexposure.com/.

Final action points for analysts

Stress‑test working capital against a 10–20% slowdown in distributor receipts and re‑price assumptions for government rebates.
Value international royalties conservatively and treat exclusive distributors as options rather than direct revenue guarantees.
Monitor Premier and Vizient contracting activity closely—GPO inclusion materially increases hospital uptake for Vibativ in the near term.

For ongoing monitoring and full contract excerpts, visit the Cumberland company page at https://nullexposure.com/ and subscribe for alerts.